

MTN Regional Meeting Closing and Awards Ceremony

Sharon Hillier and Jared Baeten

What Have We Learned This Week?

- **Hot Topics:**

- HIV and STIs are still epidemic in young women, but contraceptive type is not a major contributor (ECHO)
- We need to revitalize our efforts on STIs (Marrazzo)
- ARV resistance happens, and needs to be monitored but is not a major contributor to or consequence of PrEP failure (Parikh)
- Adherence monitoring to oral PrEP using dried blood spots can provide a pretty accurate “snapshot” of product use (Anderson)

What Have We Learned This Week?

Prevention Landscape 2019:

- **TasP:** models predicting the impact of treatment as prevention did not carefully consider age and sex-related differences (Leigh Johnson)
- **Injectable cabotegravir:** study in men nearly enrolled, 1000 more to go for the women's study, injections acceptable, stay tuned (Sinead)
- **Broadly neutralizing antibodies:** may support future development of HIV vaccine (Nyaradzo)
- **F-TAF as oral PrEP:** Works in MSM, limited or no data in heterosexual men and women. How can we move forward with filling the gaps in women? (Jim Rooney)

What Have We Learned This Week?

Taking care of special populations:

– **Adolescents:**

- Young women do want HIV prevention, but taking a pill a day is difficult (Connie Celum)
- Strategies employed in REACH are supporting young women with increasing product use (Sybil Hosek)
- Working with young adolescents requires a different approach (Carolyn Akello)

– **Pregnant and breastfeeding women**

- Community and stakeholder engagement critical to studying investigational drugs in pregnant women (Bunge/Makanani)
- Breastfeeding women at high risk of HIV, and need to be included in prevention research (Dr. Maxie)

What Have We Learned This Week?

What About Anal Sex (Back Door Mysteries)?

- Dapivirine ring effectiveness not different among women reported RAI in ASPIRE (Peebles)
- Expanding *options* for people practicing RAI: Inserts (to be tested in MTN-039), rectal douches and suppositories as dosage forms being evaluated in MTN-035 (DESIRE). What will our participants choose as their preferred dosage form? (Thes Palanee-Phillips)

Dapivirine ring

- The regulatory process moves on and access planning is underway (John Steytler)
- Women wanted the ring and had high continuation with the ring over a year of use (Baeten)

In the next 15 months...



Several protocols ending.
Four protocols launching: MTN-039, 042, 043, 045.

How can we best bring the aircraft carrier MTN into dock and ensure that all protocols have a safe place to land?

Fast, Flexible, Efficient, Laser-Focused on Our Mission

September 2019

November 2020



Enrollment complete April/May 2020. Follow-up into 2021

Complete enrollment early 2020, complete study Q3 2020



MTN-039 to launch in the US and complete in Q3



First and 2nd cohort enrolled by Nov 2020; pass off to HPTN?



Enroll 200 mother-infant pairs by end of 2020

MTN-045 to complete in Uganda and Zimbabwe

The clock is ticking but we will do it!



- We have to move swiftly and execute with precision and skill to complete our studies
- The studies we are doing now are integral to the completion of our mission and we have to keep our eye on the goal
- **WE HAVE THE BEST TEAMS POSSIBLE WHO WILL WORK TO ACCOMPLISH OUR MISSION**

MTN Awards Ceremony

- REACHing Youth Award



MTN Awards Ceremony

- **MTN Community Award**

MTN Awards Ceremony

- **MTN Laboratory Award**



MTN Awards Ceremony

- Stakeholder Excellence Award



Thanks for Your Participation, Your Energy, Your passion

Each and every one of you plays a role and are critical to our success

You are in our hearts every day

Travel safely and we will look forward to seeing you next year!